IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...

The addition of anagliptin to insulin and metformin therapy may improve glycemic control in patients with type 2 diabetes while maintaining an acceptable safety profile.

David Petrus IbarsIn the same way weight varies from person to person, so do the best weight loss strategies. While some ...

The Grammy-nominated musicians discuss what's helping them manage, and why they’re using their platform to reach the Black ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Oral semaglutide was associated with more pronounced cardiovascular benefits among patients with higher baseline HbA1c in ...

Dr. Soma Mandal, a board-certified internist at Summit Health in New Providence, New Jersey, says that getting a CBC test is ...

In the realm of diabetes management and diagnosis, two tests often come into focus: the fasting glucose test and the A1c test. Both are crucial tools in assessing blood sugar levels, but they serve ...

Concurrent hypertension and type 2 diabetes elevated mortality risks more than either condition alone among adults in the US.